Skip to main content
HLS Therapeutics Inc. logo

HLS Therapeutics Inc. — Investor Relations & Filings

Ticker · HLS ISIN · US40390B3078 LEI · 549300QKXFY1J71L2D68 TSX Wholesale and retail trade
Open in API
Filings indexed 364 across all filing types
Latest filing 2021-01-04 Regulatory Filings
Country CA Canada
Listing TSX HLS

About HLS Therapeutics Inc.

https://hlstherapeutics.com/

HLS Therapeutics Inc. is a specialty pharmaceutical company focused on the acquisition and commercialization of branded medicines across North America. The company targets products that address unmet needs, primarily in the treatment of psychiatric disorders and cardiovascular disease/risk reduction. Its commercial-stage portfolio includes CLOZARIL® (clozapine) for psychiatric disorders and VASCEPA® (icosapent ethyl) for cardiovascular risk reduction. HLS also commercializes NILEMDO® (bempedoic acid) and NEXLIZET® (bempedoic acid/ezetimibe combination) for the reduction of LDL-cholesterol in patients at risk of cardiovascular disease. HLS ensures reliable market access to these essential therapies by sourcing products directly from originators and best-in-class manufacturing partners.

Recent filings

Filing Released Lang Actions
News release - English.pdf
Regulatory Filings
2021-01-04 English
News release - English.pdf
Board/Management Information Classification · 95% confidence The document is a press release announcing the nomination of John L. Welborn, Jr. to the board of directors of HLS Therapeutics Inc. It discusses the board appointment, the nominee's background, and the company's business focus. There is no financial data, no discussion of financial results, no mention of a report being attached or published, and no regulatory filing or certification. The content is clearly about a change in the company's board composition, which fits the category of Board/Management Information (MANG). The document length is about 5959 characters, which is sufficient for a detailed announcement but does not contain financial statements or other report content. Therefore, the appropriate classification is MANG with high confidence.
2020-12-21 English
News release - English.pdf
Regulatory Filings Classification · 95% confidence The document is a press release from HLS Therapeutics announcing updates on Health Canada filings for their products MyCare and Trinomia. It discusses regulatory approval status, including Health Canada's approval of MyCare Psychiatry Lab Assays and a Notice of Deficiency for Trinomia. The document is an announcement of regulatory and product development updates rather than a financial report, earnings release, or detailed management discussion. It does not contain financial statements, earnings data, or detailed management analysis. It is not a report publication announcement since it is a substantive press release with detailed information on regulatory filings and product status. The content fits best under Regulatory Filings (RNS) as it is a general regulatory announcement about Health Canada approvals and notices, which do not fit into other more specific categories like earnings, capital updates, or management changes.
2020-12-16 English
News release - English.pdf
Regulatory Filings
2020-12-14 English
News release - English.pdf
Regulatory Filings
2020-11-19 English
News release - English.pdf
Regulatory Filings Classification · 95% confidence The document is a press release announcing Health Canada approval of a pharmaceutical product (PERSERIS) for the treatment of schizophrenia. It contains no financial data, no regulatory filing references, no meeting or voting information, no management or board changes, no earnings or interim report data, and no detailed financial or operational analysis. It is a corporate announcement about product approval and commercial strategy. This type of document fits best under Regulatory Filings (RNS) as a general regulatory announcement that does not fit into other specific categories.
2020-11-17 English

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.